Skip to main content
Caplight Logo









AviadoBio

AviadoBio

Private
LondonHealthcare & Life Scienceshttps://aviadobio.com/

Last Round

Grant

Mar 31, 2026

Total Funding Raised

$151.89M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

AviadoBio is a biotechnology company that develops innovative gene therapies aimed at transforming the lives of individuals affected by severe neurodegenerative diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyprecision gene silencingblood-brain barrierneurodegenerative diseasecapsid technologybiotechRNAivMiXTfR1 CapXgenetic medicinedrug discoverytauopathiesclinical-stage biotechlicensing agreementCNS therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AviadoBio Comparables

Compare AviadoBio with similar companies based on industry and business-model similarity.

AviadoBio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Coave Therapeutics
84%
Capsida Biotherapeutics
81%
DegenRx B.V.
79%

AviadoBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 31, 2026
StrategicOct 8, 2024
Series ADec 2, 2021
SeedApr 1, 2021
SeedDec 1, 2020

Key People

Founding team and executive leadership

Lisa Deschamps

Chief Executive Officer Board Member

Executive Team

Graeme Fielder

Chief Operating Officer

Executive Team

AviadoBio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 27, 2026

    Combining RNAi platform with TfR1 capsid for CNS gene silencing.

  • Apr 27, 2026

    Presenting drug candidate data at the ASGCT Annual Meeting.

Recent news

Latest coverage and updates

  • is_developingJun 17, 2026

    AviadoBio Ltd is developing discovery engine for the vMiX platform on Jul 1st '20.

  • partners_withJun 16, 2026

    AviadoBio Ltd partnered with Kings College London on Jul 1st '20.

AviadoBio Filings

Explore SEC and related filing metadata, where available.

AviadoBio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about AviadoBio's valuation, stock price, and market status.

Is AviadoBio a public or private company?

AviadoBio is a private company.

What is the current stock price of AviadoBio?

AviadoBio is a private company with no public stock price. No recent secondary market data is available.

How much is AviadoBio worth (valuation)?

Valuation information for AviadoBio is not publicly available.

Can I buy AviadoBio stock?

AviadoBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was AviadoBio's last funding round?

AviadoBio's most recent funding round was Corporate Funding on October 8, 2024.

Who are the main investors in AviadoBio?

Key investors in AviadoBio include New Enterprise Associates (NEA), Monograph Capital.

Will AviadoBio IPO soon?

No public IPO plans have been announced for AviadoBio.

How can I track AviadoBio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor AviadoBio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersLondon
Employee Range49
Year Founded2019
Last FundingMar 31, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?